Search company, investor...

Predict your next investment

Asset/Investment Management

Investments

30

Portfolio Exits

8

About Avidity Partners

Avidity Partners is an investment firm based in Dallas, Texas.

Headquarters Location

Dallas, Texas,

United States

Want to inform investors similar to Avidity Partners about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Research containing Avidity Partners

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Avidity Partners in 1 CB Insights research brief, most recently on Aug 2, 2021.

Latest Avidity Partners News

Innovaccer Raises $150 M Series E Round At $3.2 Billion Valuation

Dec 22, 2022

Innovaccer Inc. announced a $150 million Series E round at a $3.2 billion valuation, driven by rapid customer adoption of the Innovaccer Health Cloud. The round was led by Mubadala Capital, with participation from existing investors B Capital Group, Microsoft’s M12 fund, OMERS Growth Equity, Dragoneer, Steadview Capital, Tiger Global Management, and new investors Whale Rock Capital Management, Avidity Partners, and Schonfeld Strategic Advisors. Innovaccer’s Series E round brings the total capital raised by the company to over $375 million. At a time when healthcare organizations around the world are rapidly digitizing and transforming the way they deliver patient care, Innovaccer has embarked on a mission to connect and curate the world’s healthcare information to make it accessible and useful. Founded in 2014, Innovaccer has built the Innovaccer Health Cloud, a complete software platform used by leading healthcare organizations—including Orlando Health, MercyOne, and CommonSpirit Health—that unifies previously siloed data and helps them achieve better care quality at lower cost. “We’ve reached a turning point in healthcare, where the world of fragmented, fee-for-service ‘sick care’ is giving way to a new world of integrated, value-based, preventive care,” said Abhinav Shashank, cofounder and CEO of Innovaccer. “The electronic health record (EHR) brought healthcare into the digital world, but in many ways it has become an impediment to digital transformation due to its rigid architecture and lack of interoperability. Providers, payers, and life sciences companies recognize the urgent need for a new, open platform that brings all healthcare data together to provide a singular view of the patient, and enables friction-free care across the entire patient journey. This is the future of health everyone wants, and this is exactly what we are building with the Innovaccer Health Cloud.” “We have been investors in Innovaccer since 2019, and believe that the company has all the necessary pillars to define the new gold standard of how the Health Cloud should be implemented by providers, payers, and life sciences companies,” said Alaa Halawa, Partner and Head of the U.S. Ventures business at Mubadala Capital. “Hundreds of tech companies have tried to create a common data framework to connect the healthcare industry, but they all fell short due to extreme industry complexities or technology challenges. But in just a few short years, Innovaccer has built the most successful data activation platform in the healthcare industry as proven by record rates of industry adoption. Innovaccer is likely the first and only company since the invention of the EHR that has the opportunity to unify the healthcare ecosystem.” Innovaccer achieves critical mass in the healthcare ecosystem To date, Innovaccer has signed more than 50 customers, including recent wins with One Medical, Roche, CommonSpirit Health, Franciscan Health, Dayton Children’s Health Partners, St. Luke’s Health System, Sentara Healthcare, Adventist Health, Children’s Health Alliance, Premier Health, Atlantic Health System, Providence, Cityblock Health, Florence Health, and Zus Health, among others. Innovaccer’s ability to help its customers accelerate their transformation and innovation goals is at the core of its value proposition. “Our collaboration with Innovaccer is creating a new generation of clinical decision support tools across a wide range of use cases—from antimicrobial stewardship to oncology—that will empower clinicians to deliver more precise, personalized care,” said Sukhveer Singh, Global Head of Healthcare Insights, Roche Information Solutions. “We see huge potential to create new value for patients and clinicians. The Innovaccer Health Cloud will allow us to accelerate time-to-market and build perpetual innovation into our solution portfolio, positioning Roche to extend our legacy of clinical innovation.” Innovaccer plans to use its new funding to invest in R&D and recruit new hires as it rapidly scales its customer experience, product, and engineering talent. The company intends to release a new portfolio of Innovation Accelerators in 2022 that will help healthcare organizations tackle the most common and high-impact use cases in a fraction of the time associated with traditional methods and technologies. Share this article:

Avidity Partners Investments

30 Investments

Avidity Partners has made 30 investments. Their latest investment was in UpStream Care as part of their Series B on December 12, 2022.

CBI Logo

Avidity Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/1/2022

Series B

UpStream Care

$140M

Yes

8

10/6/2022

Series A

Nested Therapeutics

$90M

Yes

13

7/6/2022

Series C

Prellis Biologics

$35M

Yes

3

4/21/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/7/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/1/2022

10/6/2022

7/6/2022

4/21/2022

2/7/2022

Round

Series B

Series A

Series C

Series A

Series B

Company

UpStream Care

Nested Therapeutics

Prellis Biologics

Subscribe to see more

Subscribe to see more

Amount

$140M

$90M

$35M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

8

13

3

10

10

Avidity Partners Portfolio Exits

8 Portfolio Exits

Avidity Partners has 8 portfolio exits. Their latest portfolio exit was AN2 Therapeutics on March 25, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/25/2022

IPO

$99M

Public

12

12/21/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/23/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/21/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/18/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/25/2022

12/21/2021

7/23/2021

6/21/2021

6/18/2021

Exit

IPO

Acquired

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

12

10

10

10

10

Avidity Partners Team

1 Team Member

Avidity Partners has 1 team member, including current Founder, President, Managing Partner, Michael Gregory.

Name

Work History

Title

Status

Michael Gregory

Highland Capital Management

Founder, President, Managing Partner

Current

Name

Michael Gregory

Work History

Highland Capital Management

Title

Founder, President, Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.